Page last updated: 2024-11-02

pargyline and Cardiac Hypertrophy

pargyline has been researched along with Cardiac Hypertrophy in 2 studies

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research Excerpts

ExcerptRelevanceReference
"Pretreatment with propranolol and pargyline protected against ISO-induced necrosis and myocardial hypertrophy, but did not influence the ISO-induced depletion of NE stores."1.25Alterations in norepinephrine pattern in the damaged myocardium in the rat. ( Bhagat, B; Dhalla, NS; Sullivan, JM, 1975)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bhagat, B1
Sullivan, JM1
Dhalla, NS1
Stanton, HC1
Bowman, Z1
Cooper, CM1

Other Studies

2 other studies available for pargyline and Cardiac Hypertrophy

ArticleYear
Alterations in norepinephrine pattern in the damaged myocardium in the rat.
    Recent advances in studies on cardiac structure and metabolism, 1975, Volume: 6

    Topics: Animals; Cardiomegaly; Cardiomyopathies; Isoproterenol; Male; Monoamine Oxidase; Myocardium; Necrosi

1975
Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats.
    Toxicology and applied pharmacology, 1970, Volume: 16, Issue:1

    Topics: Animals; Carbon Isotopes; Cardiomegaly; DNA; Female; Glycine; Isocarboxazid; Isoniazid; Isoprotereno

1970